dexmedetomidine
dexmedetomidine: developed by 2 companies · 21 clinical trials tracked · 1 FDA decision.
dexmedetomidine evidence translation
What we can confirm
1 FDA record · 21 tracked trials
What it means
What to watch
Prepared research question
What is verified about dexmedetomidine, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 3 study sponsors
Related indications
Development Pipeline (3)
| Company | Phase |
|---|---|
| BioXcel Therapeutics, Inc. (BTAI) Agitation,Psychomotor; Agitation | Phase 2 |
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
| DR REDDYS LABORATORIES LTD (RDY) | Approved |
Clinical Trials (21)showing 10 most recent
An Alpha2-adrenoceptor Agonist to Reduce Locus Coeruleus Activity During Sleep in Adults With Insomnia Disorder: a Pilot Randomised Placebo-controlled Cross-over Study
Primary endpoint: Electrographic (EEG) signatures
Evaluation of an Opioid-Free Approach in Sedation Method Selection in Endoscopy Units: A Prospective Randomized Observational Double-Blind Comparison of Dexmedetomidine (Opioid-Free) and Remifentanil-Dexmedetomidine (Opioid-Based) Combination
Primary endpoint: Incidence of Opioid-Related Adverse Symptoms
Prevention/Reduction of ASRs and PTSD to Sustain Civilian Performance With a Sublingual Formulation of Dexmedetomidine (BXCL501)
Primary endpoint: Change in ASD Score
Dexmedetomidine Versus Fentanyl-Midazolam Combination to Attenuate the Stress Response in Laparoscopic Cholecystectomy
Primary endpoint: Hemodynamics
A Randomized Comparison Between 0.67 mcg/kg, 1 mcg/kg, and 1.33 mcg/kg of Perineural Dexmedetomidine for Ultrasound-Guided Infraclavicular Block
Primary endpoint: Motor block duration
Differences in C-Reactive Protein Levels Between Traumatic Brain Injury Patients Receiving Dexmedetomidine and Those Not Receiving Dexmedetomidine Undergoing Craniotomy at Prof. Dr. Margono Soekarjo Regional General Hospital, Purwokerto
Primary endpoint: Change in C-Reactive Protein (CRP) Levels
Efficacy of Dexmedetomidine Versus Midazolam Sedation on Extubation Time in Mechanically Ventilated Preterm Infants: a Randomized Controlled Multicenter Trial - DEXPRE
Primary endpoint: Time, measured in minutes, is evaluated from the discontinuation of the experimental treatment (either dexmedetomidine-based or midazolam-based sedation) to extubation.
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm: Outpatient Follow-up of Mental Health INDices (SDATE OF MIND)
Primary endpoint: Post-traumatic stress disorder symptoms
Dexmedetomidine as an Adjuvant to Bupivacaine in Bilateral Pectoral Nerve Blocks for Postoperative Pain Control After Cardiac Surgeries: A Randomized Controlled Trial
Primary endpoint: The duration of analgesia
Study Evaluating Dexmedetomidine in the Acute Treatment of Electrical Storm
Primary endpoint: The primary outcome is a composite of the following: 1. All-cause in-hospital death AND/OR 2. Any in-hospital ventricular arrhythmia requiring treatment after study drug initiation.
FDA Decisions1 records
Frequently asked questions
Who is developing dexmedetomidine?
dexmedetomidine is being developed by BioXcel Therapeutics, Inc., DR REDDYS LABORATORIES LTD.
How many clinical trials involve dexmedetomidine?
BioSniper tracks 21 clinical trials involving dexmedetomidine.
What is dexmedetomidine's latest FDA decision?
The most recent tracked FDA decision for dexmedetomidine is Approval for 1 INDICATIONS AND USAGE Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection is a alpha 2 adrenergic receptor agonist indicated for: • Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer Dexmedetomidine Injection and Dexmedetomidine in 5% Dextrose Injection by continuous infusion not to exceed 24 hours. (1.1) • Sedation of non-intubated adult patients prior to and/or during surgical and other proce, dated February 25, 2026.